Hormone Receptor-positive Breast Cancer

ETHAN - ET for Male BC

VS-6766+Abema+Fulv in Met HR+/HER- BC

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Study of Screening Brain MRIs in Stage IV Breast Cancer

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

RWE About QOL and Compliance of Patients With OFS in China

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

TH1902 in Patients With Advanced Solid Tumors

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

PRE-I-SPY Phase I/Ib Oncology Platform Program

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer